Mankind Pharma Limited FII & DII Activity

Today's Institutional Flow

FII cash buying reaches ₹871.83 Cr, while DII cash buying totals ₹643.35 Cr, indicating a net institutional inflow of ₹1,515.18 Cr into the market today and underscoring a pronounced preference for equity exposure among foreign investors. The foreign side shows a stronger appetite, outpacing domestic investors by roughly ₹228.48 Cr, and this differential reflects a shift toward risk‑on positioning as broader market sentiment improves. No block or bulk transactions are recorded for MANKIND on the day, confirming that the observed flow is purely driven by routine cash purchases rather than large strategic trades.

Trend vs 5‑Day Average

The day’s FII cash net of +₹871.83 Cr contrasts sharply with a five‑day average outflow of ₹‑894.74 Cr, signalling a reversal toward buying pressure that aligns with the recent rebound in global risk assets. Conversely, DII cash continues its upward trajectory, exceeding the five‑day average of +₹2,592.03 Cr, which suggests that domestic funds are maintaining their aggressive accumulation of pharmaceutical equities.

F&O Positioning Data

FII F&O positions register a net long of ₹643,395 Cr, reflecting aggressive derivative exposure that amplifies the underlying cash bias and signals confidence in continued market upside. Their index‑futures stance shows a long‑to‑short ratio of 1.2, suggesting a modest bias toward market upside while still retaining a hedge against short‑term volatility.

Healthcare Sector Flow

Recent weeks have seen the healthcare segment attract steady DII inflows while FII activity remains comparatively muted, highlighting a domestic‑driven rally in pharma stocks that could benefit companies like MANKIND as investors chase growth narratives in the sector.